ATE314393T1 - Verzögerte freigabe von insulinotropin (glp-1) - Google Patents

Verzögerte freigabe von insulinotropin (glp-1)

Info

Publication number
ATE314393T1
ATE314393T1 AT94300981T AT94300981T ATE314393T1 AT E314393 T1 ATE314393 T1 AT E314393T1 AT 94300981 T AT94300981 T AT 94300981T AT 94300981 T AT94300981 T AT 94300981T AT E314393 T1 ATE314393 T1 AT E314393T1
Authority
AT
Austria
Prior art keywords
glp
insulinotropine
delayed release
administration
peptides
Prior art date
Application number
AT94300981T
Other languages
English (en)
Inventor
Dennis Edward Danley
Robert Alan Gelfand
Kieran Francis Geoghegan
Kim Yesook
William Joseph Lambert
Qi Hong
Original Assignee
Scios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc filed Critical Scios Inc
Application granted granted Critical
Publication of ATE314393T1 publication Critical patent/ATE314393T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Communication System (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT94300981T 1993-04-07 1994-02-10 Verzögerte freigabe von insulinotropin (glp-1) ATE314393T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4413393A 1993-04-07 1993-04-07

Publications (1)

Publication Number Publication Date
ATE314393T1 true ATE314393T1 (de) 2006-01-15

Family

ID=21930680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94300981T ATE314393T1 (de) 1993-04-07 1994-02-10 Verzögerte freigabe von insulinotropin (glp-1)

Country Status (18)

Country Link
EP (1) EP0619322B1 (de)
JP (5) JPH072695A (de)
KR (1) KR100186885B1 (de)
CN (2) CN1080123C (de)
AT (1) ATE314393T1 (de)
AU (1) AU682328B2 (de)
BR (1) BR9401185A (de)
CA (1) CA2116478C (de)
CZ (1) CZ296341B6 (de)
DE (1) DE69434588T2 (de)
ES (1) ES2255051T3 (de)
HU (1) HU225496B1 (de)
IL (1) IL108611A (de)
NO (1) NO318804B1 (de)
NZ (1) NZ250844A (de)
PL (1) PL180697B1 (de)
RU (1) RU2126264C1 (de)
ZA (1) ZA94878B (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
JPH0682743A (ja) * 1992-09-04 1994-03-25 Sony Corp 強誘電性液晶組成物
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
EP0658568A1 (de) * 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU4298596A (en) * 1994-12-23 1996-07-19 Novo Nordisk A/S Protracted glp-1 compositions
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
JP2001503963A (ja) * 1996-02-06 2001-03-27 イーライ・リリー・アンド・カンパニー 糖尿病治療
CN1198100A (zh) * 1996-06-11 1998-11-04 佐纳根有限公司 聚氨基葡糖药物投递系统
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
DE69831421T2 (de) * 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
AU1617399A (en) * 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE269103T1 (de) 1998-03-13 2004-07-15 Novo Nordisk As Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
ATE445006T1 (de) 1998-08-10 2009-10-15 Us Gov Health & Human Serv Differenzierung von nicht-insulin in insulin- produzierende zellen durch glp-1 und exendin-4 und dessen verwendung
KR20010073033A (ko) * 1998-08-28 2001-07-31 피터 지. 스트링거 인슐리노트로픽 펩티드의 투여 방법
EP1666054A1 (de) * 1998-08-28 2006-06-07 Eli Lilly & Company Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CN1372570A (zh) 1999-04-30 2002-10-02 安米林药品公司 修饰的exendin和exendin激动剂
WO2001030373A1 (en) * 1999-10-28 2001-05-03 Institut Neftekhimicheskogo Sinteza Imeni A.V.To Pchieva Rossiiskoi Akademii Nauk (Inkhs Ran) Polypeptide composition
EP1396499A3 (de) * 2000-01-27 2004-12-29 Eli Lilly And Company Verfahren zur Lösung von Glucagon-ähnlichen Peptid-1 (GLP-1) Verbindungen
BR0107837A (pt) 2000-01-27 2003-01-14 Lilly Co Eli Processo para solubilização de compostos peptìdeo 1 semelhantes a glucagon
AU2001228327A1 (en) * 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
PL377591A1 (pl) * 2002-10-02 2006-02-06 Zealand Pharma A/S Stabilizowane związki eksendyny-4
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
JP4548335B2 (ja) * 2003-03-07 2010-09-22 味の素株式会社 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤
EA009366B1 (ru) * 2003-03-19 2007-12-28 Эли Лилли Энд Компани Связанные с полиэтиленгликолем соединения гпп-1
PT1656370E (pt) 2003-06-03 2012-11-29 Rib X Pharmaceuticals Inc Compostos biaril-heterocíclicos e métodos de os produzir e de os utilizar
RU2246964C1 (ru) * 2003-10-23 2005-02-27 Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГОУВПО СибГМУ) Средство, обладающее гиполипидемическим, антиоксидантным и гипогликемическим действием, для лечения сердечно- сосудистых и эндокринных заболеваний и способ его применения
EP1694356B1 (de) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulierung der nahrungspräferenz mit glp-1-agonisten
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
NZ565535A (en) 2005-06-30 2011-03-31 Ipsen Pharma Sas GLP-1 pharmaceutical compositions
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
MX2008013168A (es) * 2006-04-13 2008-10-27 Sod Conseils Rech Applic Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
MX2008013304A (es) 2006-04-20 2008-10-27 Amgen Inc Compuestos de peptido 1 tipo glucagon.
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR20130133104A (ko) * 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
CA2733005C (en) * 2008-08-07 2016-09-27 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
EP2328922A4 (de) * 2008-08-07 2013-01-02 Ipsen Pharma Sas Analoga des glucoseabhängigen insulinotropen polypeptids
CN102281865B (zh) * 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
EP2216042A1 (de) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Glp-1 polymer conjugates having a releasable linkage
US20120157382A1 (en) 2010-12-21 2012-06-21 Siegfried Krimmer Pharmaceutical glp-1 compositions having an improved release profile
US20140045754A1 (en) * 2011-01-19 2014-02-13 Joern Drustrup Glp-1 compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102643339B (zh) * 2011-02-21 2014-04-09 天津药物研究院 一种glp-1类似物、制备方法及其应用
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
US9528648B2 (en) 2013-03-15 2016-12-27 Opw Fueling Components Inc. Breakaway assembly with relief valve
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
EP3628683A1 (de) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
CN113912673B (zh) * 2021-11-09 2024-02-09 河南省农业科学院 一种芝麻来源的低苦味ace抑制肽及其制备方法和应用
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
WO1989003671A1 (fr) * 1987-10-29 1989-05-05 Dainippon Pharmaceutical Co., Ltd. Preparation a liberation entretenue
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
JPH04504246A (ja) * 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5069223A (en) * 1990-02-14 1991-12-03 Georgetown University Method of evaluating tissue changes resulting from therapeutic hyperthermia
DE69122517T2 (de) * 1990-06-15 1997-02-13 Schering Corp Kristallines interleukin-4
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat

Also Published As

Publication number Publication date
JP5081213B2 (ja) 2012-11-28
IL108611A0 (en) 1994-05-30
HUT68525A (en) 1995-06-28
HU225496B1 (en) 2007-01-29
ZA94878B (en) 1995-08-10
HU9400350D0 (en) 1994-05-30
JP2004099621A (ja) 2004-04-02
IL108611A (en) 2004-06-20
JP4610503B2 (ja) 2011-01-12
CZ27594A3 (en) 1995-05-17
RU2126264C1 (ru) 1999-02-20
NO318804B1 (no) 2005-05-09
JPH072695A (ja) 1995-01-06
JP2006213727A (ja) 2006-08-17
EP0619322A3 (en) 1996-03-13
DE69434588D1 (de) 2006-02-02
CN1106698A (zh) 1995-08-16
KR100186885B1 (ko) 1999-05-01
PL180697B1 (pl) 2001-03-30
JP2001158749A (ja) 2001-06-12
CN1311865C (zh) 2007-04-25
NO940436L (no) 1994-10-10
CA2116478C (en) 2002-12-03
EP0619322A2 (de) 1994-10-12
CA2116478A1 (en) 1994-10-08
CZ296341B6 (cs) 2006-02-15
AU5501694A (en) 1994-10-13
AU682328B2 (en) 1997-10-02
HK1070589A1 (en) 2005-06-24
NO940436D0 (no) 1994-02-09
BR9401185A (pt) 1994-10-18
CN1544084A (zh) 2004-11-10
DE69434588T2 (de) 2006-09-07
JP2010006841A (ja) 2010-01-14
EP0619322B1 (de) 2005-12-28
NZ250844A (en) 1996-03-26
CN1080123C (zh) 2002-03-06
ES2255051T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
ATE314393T1 (de) Verzögerte freigabe von insulinotropin (glp-1)
EP0464022A4 (en) Insulinotropic hormone
EP0336760A3 (de) Knochenwachstum induzierendes Protein
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
PL319608A1 (en) Compositions for treating irds and ards, containing at least one glucocorticosteroid in a mixture with a pulmonic surfactant
AU3888893A (en) Use of a peptide
DE68921867D1 (de) Photopolymerisierbare Zusammensetzung.
CA2138161A1 (en) Glucagon-like peptide and insulinotropin derivatives
BR9714505A (pt) para o diabetes.
DK1140148T3 (da) Lagerholdbar formulering af glucagon-agtigt peptid-1
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
CA2100745A1 (en) Amylin agonist peptides and uses therefor
FI893127A0 (fi) Komposition som bildar en vattenavstoetande film.
DE68915494D1 (de) Zubereitung mit verzögerter freigabe durch verwendung von alginaten.
DK7090D0 (da) Konvertibel stol
ES2131122T3 (es) Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
AU3171789A (en) 4-aryl-4-piperidine (or pyrrolidine or hexahydroazepine) carbinols and heterocyclic analogs thereof
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus
NO893892D0 (no) Antimikrobiologisk sammensetning og fremgangsmaate for anvendelse.
DE69407593D1 (de) Polyisocyanatzusammensetzung
IT1126709B (it) Procedimento di candeggio ottico per substrati costituiti,in parte o in totalita',da poliammidi sintetiche
DE68912432D1 (de) Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen.
RU96114697A (ru) Фармацевтическая композиция с фотосенсибилизатором
NO910062L (no) Pose for brukte engangsartikler som er benyttet ved kirurgiske operasjoner, saasom operasjonsduker og kompresser.
NO894426D0 (no) Materiale, fortrinnsvis i baandform, for anvendelse som omhyllingsmateriale.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties